KALY plans to publish an online presentation with more detail on each of the treatment developments later this month.
DALLAS, April 09, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a treatment for epilepsy derived from the company’s patented cannabis extraction method is under research and development.
“Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals,” said Kali-Extracts, CEO Frederick Ferri.
The company currently has ongoing cannabis extract research and development targeting four specific health issues, Chronic Obstructive Pulmonary Disease (COPD), Type 2 Diabetes, Cancer Pain Management and Epilepsy.
KALY plans to publish an online presentation with more detail on each of the treatment developments later this month. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is anticipated to reach $83 billion by 2024. The market for epilepsy treatment is anticipated to reach $9 billion by 2022. Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline.
